企业QQ
官方微信
MedKooCat#:206211
Name:ABT-518
CAS#:286845-00-9
ChemicalFormula:C21H22F3NO8S
ExactMass:505.10182
MolecularWeight:505.46
ElementalAnalysis:C,49.90;H,4.39;F,11.28;N,2.77;O,25.32;S,6.34
Synonym:ABT518;ABT518;ABT-518.
IUPAC/ChemicalName:N-((S)-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-((4-(4-(trifluoromethoxy)phenoxy)phenyl)sulfonyl)ethyl)-N-hydroxyformamide
InChiKey:IVPPTWCRAFCOFJ-RTBURBONSA-N
InChiCode:InChI=1S/C21H22F3NO8S/c1-20(2)30-11-19(33-20)18(25(27)13-26)12-34(28,29)17-9-7-15(8-10-17)31-14-3-5-16(6-4-14)32-21(22,23)24/h4-10,13,18-19,27H,11-12H2,1-2H3/t18-,19-/m1/s1
SMILESCode:O=CN([C@@H]([C@@H]1OC(C)(C)OC1)CS(=O)(C2=CC=C(OC3=CC=C(OC(F)(F)F)C=C3)C=C2)=O)O
ABT-518isapotentinhibitorofgelatinaseAandgelatinaseB,twomatrixmetalloproteinase(MMP)enzymesinvolvedintumorgrowthandmetastasis.ABT-518hasdemonstratedrobustantitumoractivityinavarietyofanimalmodels.Thiscompoundisapotentandselectiveinhibitoroftheseenzymetargets.
1:FattoriD,SquarciaA,BartoliS.Fragment-basedapproachtodrugleaddiscovery:overviewandadvancesinvarioustechniques.DrugsRD.2008;9(4):217-27.Review.PubMedPMID:18588353.
2:StokvisE,RosingH,BeijnenJH.Stableisotopicallylabeledinternalstandardsinquantitativebioanalysisusingliquidchromatography/massspectrometry:necessityornot?RapidCommunMassSpectrom.2005;19(3):401-7.PubMedPMID:15645520.
3:SuttonTA,KellyKJ,MangHE,PlotkinZ,SandovalRM,DagherPC.Minocyclinereducesrenalmicrovascularleakageinaratmodelofischemicrenalinjury.AmJPhysiolRenalPhysiol.2005Jan;288(1):F91-7.Epub2004Sep7.PubMedPMID:15353401.
4:WadaCK.Theevolutionofthematrixmetalloproteinaseinhibitordrugdiscoveryprogramatabbottlaboratories.CurrTopMedChem.2004;4(12):1255-67.Review.PubMedPMID:15320725.
5:StokvisE,RosingH,CrulM,RieserMJ,HeckAJ,SchellensJH,BeijnenJH.QuantitativeanalysisofthenovelanticancerdrugABT-518,amatrixmetalloproteinaseinhibitor,plusthescreeningofsixmetabolitesinhumanplasmausinghigh-performanceliquidchromatographycoupledwithelectrospraytandemmassspectrometry.JMassSpectrom.2004Mar;39(3):277-88.PubMedPMID:15039935.
6:CrulM,BeerepootLV,StokvisE,VermaatJS,RosingH,BeijnenJH,VoestEE,SchellensJH.Clinicalpharmacokinetics,pharmacodynamicsandmetabolismofthenovelmatrixmetalloproteinaseinhibitorABT-518.CancerChemotherPharmacol.2002Dec;50(6):473-8.Epub2002Oct25.PubMedPMID:12451474.
7:GumRJ,HickmanD,FagerlandJA,HeindelMA,GagneGD,SchmidtJM,MichaelidesMR,DavidsenSK,UlrichRG.Analysisoftwomatrixmetalloproteinaseinhibitorsandtheirmetabolitesforinductionofphospholipidosisinratandhumanhepatocytes(1).BiochemPharmacol.2001Dec15;62(12):1661-73.PubMedPMID:11755120.
8:WadaCK,HolmsJH,CurtinML,DaiY,FlorjancicAS,GarlandRB,GuoY,HeymanHR,StaceyJR,SteinmanDH,AlbertDH,BouskaJJ,ElmoreIN,GoodfellowCL,MarcottePA,TapangP,MorganDW,MichaelidesMR,DavidsenSK.PhenoxyphenylsulfoneN-formylhydroxylamines(retrohydroxamates)aspotent,selective,orallybioavailablematrixmetalloproteinaseinhibitors.JMedChem.2002Jan3;45(1):219-32.PubMedPMID:11754593.